Perimeter Medical Imaging Ai Inc · TSXV:PINK
Perimeter Medical Imaging Ai — Investor Presentation (2024)
24 slides from Perimeter Medical Imaging Ai's investor presentation, 2024
Slide 1: Empowering Surgeons with OCT - Investor Presentation
Va ee \\ Follow Perimeter on Social: fin} ry) e (} PERIMETER Empowering Surgeons with OCT Investor Presentation TSXV: PINK | OTC: PYNKF | FSE Perimeter Medical Imag 7 ni audience and not for use by healthcare professionals. The information contained herein should ape, £ PERIMETER
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward-looking forward statements. Words such as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” and similar words and the negative form thereof are used to identify forward-looking s
Slide 3: Indications for Use Disclosures
Indications for Use Disclosures S-Series OCT The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure, by providing two-dimensional, cross- sectional, realtime depth visualization, with image review manipulation software for identifying and an
Slide 4: Perimeter Snapshot
Perimeter Snapshot © Experienced Team Growing Market Differentiated Technology CEO and CFO transition, Opportunity First and only Optical Coherence summer 2023; management Est. 1.2 million+ oncological Tomography (OCT) system for use in team brings strong experience surgeries in the U.S. in 2024; th
Slide 5: It's All About Getting Clean Margins
It’s All About Getting Clean Margins Surgeons cannot detect remaining cancer cells (especially with hard-to-detect cancers) by sight or touch @ Pose Negative/Clean Margin Positive Margin ~ Traditional imaging used in the ie “A operating room (e.g. X-ray) does ! \ not have the resolution needed 4 I t
Slide 6: The Problem: Positive Margin
The Problem: Positive Margin 4in10 lifetime risk for cancer! Even for skilled surgeons, the odds of needing a repeat (re-excision) surgery due to positive margins are relatively high - nearly 1in 4 for some types of cancer. of breast cancer lumpectomies have a positive margin? of thyroid cancers hav
Slide 7: Perimeter - Driven to Transform Cancer Surgery
Perimeter - Driven to Transform Cancer Surgery We envision a world where patients no longer experience the emotional and physical trauma of being called back for a second surgery ~ due to cancer left behind. Beth DuPree, MD, FACS, ABOIM Breast Surgeon “The second worst phone call | have to make is c
Slide 8: The S-Series has a general indication and has not been evaluated by FDA for
The S-Series has a general indication and has not been evaluated by FDA for specific uses. For more information, visit perimetermed.com/disclosures. 8 IR-104 Rev A
Slide 9: Disruptive Platform Comprised of Key Components
Disruptive Platform Compromised of 4 Key Components i PERIMETER Aas Welcome, IN DEVELOPMENT (Se B*) S- Series Specimen Immobilizer Proprietary Wide-Field OCT (single use container) Imaging Atlas (100X coverage) Aids in positioning Provides ongoing support for diverse tissue types image review * Peri
Slide 10: Advancing the Current Treatment Paradigm
Advancing the Current Treatment Paradigm © How Does a Surgeon Know If They Achieved Clean Margins? CURRENT STANDARD OF CAR Yuu = ys Waiti Post-Op Resection D riod: Pathology/ ero Action PERIMETER SOLUTION’ — - - Visualization in Surgeon Action Post-Op Resection Perimeter OCT the OR (needed) Patholog
Slide 11: IR-104 Rev A
20% 16% 19.9%* 12% 8% 4% 5.6% 0% * 11 IR-104 Rev A
Slide 12: DCIS IDC
35% 30% 30.8% 25% 24.0% 20% 18.0% 15% 13.3% 12.7% 10% 5% 0.0% 0% DCIS IDC 12 IR-104 Rev A
Slide 13: Linked Here Linked Here Linked Here
Linked Here Linked Here Linked Here 13 IR-104 Rev A
Slide 14: Surgeons Support Clinical Fit
Surgeons Support Clinical Fit © Beth Anglin, MD, FACS Michele Carpenter, MD, FACS Breast Surgeon, TX Breast Surgeon, CA “This technology can alleviate a surgeon’s “With the Perimeter S-Series OCT*, uncertainty on margins and help address the | have a much better chance of getting possibility that th
Slide 15: Next-Gen Development: B-Series with AI
“Next-Gen” Development: B-Series* with Al ——— Alastair Thompson Professor and Chief, Section of Breast Surgery, Baylor College of Medicine “This investigational and pioneering technology* allows surgeons to examine an excised tissue sample and identify areas of concern to support ‘real-time’ margin
Slide 16: Re-Excision Rates and Costs
~19.9% Target ~5.6% Re-Excision Rate1* Re-Excision Rate2** ~$677M ~$486M ~28,600 Lumpectomies Re-excisions Lumpectomies Re-excisions ~$17K cost per re-excision 1* * 16 IR-104 Rev A
Slide 17: Potential for Significant Market Expansion
Potential for Significant Market Expansion Top 8 Cancers Represent ~$1.2B Annually in U.S. Healthcare Costs Due to Re-Excisions Approximate 5-Year Survival Rates $700,000,000 225,000 100% $600,000,000 200,000 90% 175,000 5 $50,000,000 80% 150,000 70% $400,000,000 125,000 60% $300,000,000 100,000 . 7
Slide 18: IR-104 Rev A
• • • • • • • • • • • • • • • • 18 IR-104 Rev A
Slide 19: Several Longer-Term Platform Expansion Opportunities
Several Longer-Term Platform Expansion Opportunities © Our Core Technology Can Be Reconfigured to Address Multiple Clinical Applications Biopsy Core Assessment Tumour Margin Assessment = a Reduce need for oversampling Providing Real Time A ‘of and resulting processing of roviding Real Time Assessmen
Slide 20: Opportunity is Well-Protected
Opportunity is Well-Protected © * 6issued patents, with another 2 patents pending approval in U.S. and internationally, related to: + Advanced image processing/reconstruction algorithms + Al auto image assessment algorithms + Visualization of algorithm output and imaging data + Tissue management sys
Slide 21: Capital Structure
Capital Structure Ticker Symbol TSXV: PINK | OTC: PYNKF | FSE: 4PC COMMON MARKET SHARES CAPITALIZATION 65,052,822 ~C$32MM MAJOR SHAREHOLDERS SC Master Holdings, LLC, 22.2% CASH & CASH EQUIVALENTS USD$10.6 million” * At end of Ql 2024 Analyst Coverage FIRM Leede Jones Gable Paradigm Capital Raymond J
Slide 22: Deep Knowledge of AI & Medical Technology Space
Deep Knowledge of AI & Medical Technology Space 22 IR-104 Rev A
Slide 23: In Summary
In Summary Current solution addressing $1B+ cancer market, with 75% gross margin recurring revenue model Very positive reception from early adopters; accelerating commercialization Significant market expansion opportunities (10x - other tissues, 4x - global expansion) Very valuable technology patent
Slide 24: IR-104 Rev A
Follow Perimeter on Social: Fin} ry} r+) Oo (©) PERIMETER TSXV: PINK | OTC: PYNKF | FSE: 4PC For more information, contact: investors@perimetert
Perimeter Medical Imaging AI — Investor Presentation (2024) on 6ix